SMG1

Across TCGA pan-cancer cohorts, SMG1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SMG1 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SMG1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SMG1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where SMG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.724	0.943	<.001	56	view →
PDAC	DFS	Quartile	All	0.578	0.881	<.001	50	view →
LSCC	DFS	Quartile	All	0.848	0.562	.004	5	view →
LUAD	DFS	Median	III,IV	0.699	0.315	.021	4	view →
GBM	DFS	Tertile	All	0.331	0.513	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SMG1–CCRCC (OS)

Open the CCRCC breakdown →